- Datum10.06.2026
- Uhrzeit12:00 - 13:00 Uhr
- Veranstalter
stock3
Tarsus Pharmaceuticals Inc. Registered Shares DL-,0001 Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Société Générale | VK | |||||
| Nasdaq | VK | |||||
| Nasdaq Basic | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,17 %
Intraday
-4,59 %
1 Woche
-6,62 %
1 Monat
-27,45 %
Seit Jahresbeginn
38,30 %
1 Jahr
276,90 %
3 Jahre
78,27 %
5 Jahre
Passender Service zu Tarsus Pharmaceuticals Inc. Registered Shares DL-,0001
Webinar zu Tarsus Pharmaceuticals Inc. Registered Shares DL-,0001
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)38,510-85,250
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Tarsus Pharmaceuticals Inc. Registered Shares DL-,0001
Keine Dividenden verfügbar
Termine von Tarsus Pharmaceuticals Inc. Registered Shares DL-,0001
Keine aktuellen Termine
Beschreibung
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
